Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 12Lymphoma 9Lymphoma, T-Cell 8Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Hematologic Neoplasms 3Urinary Bladder Neoplasms 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Colorectal Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thrombocythemia, Essential 1

Interventions

fludarabine 3itacitinib 2Alemtuzumab 2thymoglobulin 1ruxolitinib 1romidepsin 1niraparib 1nelarabine 1fludarabine phosphate 1duvelisib 1Stem Cell Transplantation 1Interleukin-15 1INCB039110 1GRN163L peptide 1Everolimus 1Depsipeptides 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Prolymphocytic, T-Cell × romidepsin × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡